Cellspect key facts
as of Oct 2026- Developer of in-vitro diagnostic agents and medical devices designed to offer the prognosis of endometriosis progression.
- Cellspect is valued at approximately $142.1M as of Oct 2026 (last reported valuation).
- It has raised $22.6M; the latest was Later Stage VC in May 2025.
- Notable investors include Mitsubishi UFJ Capital, FASTAR, MCP Partners, Tokyo University of Science Investment Management, Aflac Ventures Japan — 15 tracked in total.
- Status: Privately Held (backing).
Cellspect's last reported valuation, May 2019. Nothing priced has surfaced since.
- ·The complete investor list: 15 names
- ·Watch Cellspect: the Monday email on marks, rounds and moves
Cellspect funding rounds
No funding rounds for Cellspect are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Cellspect
15+Cellspect valuation
Cellspect's last reported valuation was $142 million in May 2019. No priced round, secondary trade or fund mark has surfaced since.
Cellspect investors
15 investors are on record for Cellspect, including Mitsubishi UFJ Capital, FASTAR, MCP Partners and Tokyo University of Science Investment Management.
About Cellspect
Developer of in-vitro diagnostic agents and medical devices designed to offer the prognosis of endometriosis progression. The company's devices develop analytical instruments and diagnostic agents related to point-of-care testing to make medical treatment more familiar and contribute to the improvement by making diagnosis results on the cloud, enabling patients to get prompt and appropriate consultation about endometriosis progression and cancer treatment.
- Sector
- Healthcare
- HQ
- Morioka, Japan
- Founded
- 2014
- Employees
- 50
- Website
- cellspect.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.